Pillar · Metabolic research
Weight Loss and Metabolic Peptides: The Research Evidence
Metabolic peptide research is dominated by the incretin axis — the gut hormones released after eating that modulate insulin secretion, gastric emptying and appetite signalling in the brain. This hub covers the pharmacology of GLP-1, GIP, glucagon and amylin receptor agonists, what the published trials actually measured, and how single-, dual- and triple-receptor agonists differ mechanistically.
Evidence position
Established clinical evidence
Research evidence, established clinical evidence and regulatory approval are three different things. This page distinguishes them throughout and does not present research compounds as approved treatments.
The incretin effect
An oral glucose load produces a substantially larger insulin response than the same amount of glucose given intravenously. That difference is the incretin effect, and it is mediated principally by GLP-1 and GIP released from the intestine. Both are degraded within minutes by dipeptidyl peptidase-4, which is why native GLP-1 is useless as a pharmacological agent and why every clinical analogue is engineered for protease resistance.
From single receptor to multi-receptor pharmacology
The field moved through three generations in roughly a decade. First came GLP-1 receptor agonists. Then dual GIP/GLP-1 agonists, which add a second incretin receptor and appear to alter adipose handling of nutrients as well as insulin secretion. Most recently, triple agonists add glucagon receptor activity, which in trials was associated with increased energy expenditure alongside reduced intake — a different mechanism to appetite suppression alone.
Amylin receptor agonists represent a parallel line, targeting satiety signalling through the area postrema rather than the incretin receptors, and are studied both alone and in fixed combination with incretin agonists.
Reading metabolic trial data honestly
Weight-change percentages from different trials are frequently compared as if they were measured identically. They usually were not: trial duration, background lifestyle intervention, dose-escalation schedule, discontinuation handling and the statistical estimand all differ. Cross-trial percentage comparisons are indicative at best and should not be presented as head-to-head results.
Gastrointestinal adverse events dominate the tolerability profile of this class across trials, and discontinuation rates are a more informative signal than mean efficacy figures alone.
Compounds studied in this area
| Compound | What it is | Evidence tier |
|---|---|---|
| GLP-1 receptor agonists | Single-incretin-receptor analogues; the most extensively trialled group in the class. | Established clinical evidence |
| GIP/GLP-1 dual agonists | Two incretin receptors engaged by one molecule. | Established clinical evidence |
| GIP/GLP-1/glucagon triple agonists | Adds glucagon-receptor activity and an energy-expenditure component; still in trial programmes. | Emerging human research |
| Amylin receptor agonists | Satiety signalling via a non-incretin pathway; studied alone and in combination. | Emerging human research |
Comparisons in this cluster
Key takeaways
- Metabolic peptide research is dominated by the incretin axis — the gut hormones released after eating that modulate insulin secretion, gastric emptying and appetite signalling in the brain. This hub covers the pharmacology of GLP-1, GIP, glucagon and amylin receptor agonists, what the published trials actually measured, and how single-, dual- and triple-receptor agonists differ mechanistically.
- Overall evidence position for this topic: established clinical evidence.
- Findings in cells or animals are hypotheses about humans, never demonstrations in humans.
- Nothing on this page is medical advice, a protocol, or a dosing recommendation.
Frequently asked questions
What are weight loss peptides?
A shorthand for peptide analogues studied in metabolic research — chiefly incretin receptor agonists and amylin analogues. Some members of the class are approved medicines; others are investigational compounds with no approval.
What is the difference between a single, dual and triple agonist?
The number of receptors the molecule activates. Single agonists engage GLP-1; dual agonists add GIP; triple agonists add glucagon, which in trials was linked to increased energy expenditure rather than intake reduction alone.
Can trial results for different compounds be compared directly?
Not reliably. Unless the compounds were studied head-to-head in the same trial, differences in design, duration and analysis make percentage comparisons indicative only.
Continue reading
Related research hubs
Peptide Science
How peptides are built, how they signal, how they are synthesised and how they are studied — the foundational science behind every other topic on this site.
Peptide Research & Clinical Trials
How peptide research is conducted and graded — trial phases, endpoints, evidence hierarchy, and how to read a peptide study without over-reading it.
Peptide Safety
What is actually known about peptide safety — immunogenicity, contamination, unknown long-term profiles, and why absence of reported harm is not evidence of safety.
Peptide Comparisons
Head-to-head peptide comparisons built on evidence tables — mechanism, pharmacology, study base and limitations, without unsupported superiority claims.
About this page
Written and reviewed by the Peptide Intel Hub Editorial Team. Last reviewed 8 September 2026.
Scientific disclaimer: this page is educational and does not constitute medical advice. Research compounds referenced here are not approved treatments. See our research disclaimer.